MM-310, an anti-EphA2 immuno-liposome containing docetaxel prodrug has shown superior tumor penetration and anti-tumor activity in a range of xenograft models compared to free docetaxel and significantly with lower toxicity (130). Here, EPHA2 is linked to neoplasm.